Eli Lilly & Co.’s full-year earnings forecast came in line with analysts’ estimates as the company works to fix inventory ...

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

Today, the American Diabetes Association® (ADA) announced a new suite of resources to support improved care for those living ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...